menu
    • menu
    [{"orgOrder":0,"company":"TC BioPharm","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"TCB 008-001","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ EF Hutton","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPharm \/ EF Hutton"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"cyclophosphamide","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPharm \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"TCB-008","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Queen Mary University of London","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Queen Mary University of London","highestDevelopmentStatusID":"2","companyTruncated":"TC BioPharm \/ Queen Mary University of London"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"TCB-008","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"TCB008","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"OmnImmune","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPharm \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPharm \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPharm \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"OmnImmune","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"OmnImmune","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"ScaleReady","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TC BioPharm \/ ScaleReady","highestDevelopmentStatusID":"12","companyTruncated":"TC BioPharm \/ ScaleReady"}]

    Find Clinical Drug Pipeline Developments & Deals by TC BioPharm

    Menu

    TC BioPharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OmnImmune,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : ScaleReady

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

                            Details : The grant will support TCB008 manufacturing process optimizations. OmnImmune is an allogeneic unmodified cell therapy for the treatment of patients suffering from relapse/refractory AML.

                            Brand Name : TCB008

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 12, 2024

                            Lead Product(s) : OmnImmune,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : ScaleReady

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OmnImmune,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial

                            Details : TCB008 (omnImmune) is an allogeneic unmodified cell therapy consisting activated and expanded gamma delta T cells. It is under trial for treatment of patients suffering from relapse/refractory AML.

                            Brand Name : TCB008

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 20, 2024

                            Lead Product(s) : OmnImmune,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OmnImmune

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial

                            Details : TCB008 (omnImmune) is an allogeneic unmodified cell therapy consisting activated and expanded gamma delta T cells. It is under trial for treatment of patients suffering from relapse/refractory AML.

                            Brand Name : TCB008

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 12, 2024

                            Lead Product(s) : OmnImmune

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OmnImmune

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox

                            Details : TCB008 (omnImmune) is an allogeneic unmodified cell therapy consisting activated and expanded gamma delta T cells. It is under trial for treatment for Monkey Pox.

                            Brand Name : TCB008

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 06, 2024

                            Lead Product(s) : OmnImmune

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering

                            Details : The Company intends to use the net proceeds to support its upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia evaluating OmnImmune, an allogeneic gamma delta T cell product.

                            Brand Name : OmnImmune

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 28, 2024

                            Lead Product(s) : Allogeneic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $2.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            TC BioPharm Announces Closing of $2.0 Million Public Offering

                            Details : The proceeds will advance TC Biopharm's preclinical and clinical pipeline, including OmnImmune, an unmodified allogeneic gamma delta T cell product, being initially used for the treatment of AML.

                            Brand Name : OmnImmune

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 15, 2024

                            Lead Product(s) : Allogeneic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $2.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $2.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            TC BioPharm Announces Pricing of $2.0 Registered Direct Offering

                            Details : The proceeds will advance TC Biopharm's preclinical and clinical pipeline, including OmnImmune, an unmodified allogeneic gamma delta T cell product, being initially used for the treatment of AML.

                            Brand Name : OmnImmune

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 13, 2024

                            Lead Product(s) : Allogeneic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $2.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $3.8 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds

                            Details : The net proceeds will be used to support company's upcoming clinical trial focusing on relapse/refractory AML evaluating OmnImmune, an unmodified allogeneic gamma delta T cell product.

                            Brand Name : OmnImmune

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 06, 2024

                            Lead Product(s) : Allogeneic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $3.8 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCB008

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

                            Details : TCB008 (omnImmune) is an allogeneic unmodified cell therapy with activated gamma delta T cells. It is in phase 2 trials for relapse/refractory Acute Myeloid Leukemia (AML).

                            Brand Name : TCB008

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 22, 2024

                            Lead Product(s) : TCB008

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            TC BioPharm

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Gamma Delta T-cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $3.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            TC BioPharm Announces Closing of $3.5 Million Public Offering

                            Details : The Company intends to use the net proceeds to support its upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, evaluating OmnImmune, an allogeneic unmodified cell therapy that consists of activated and expanded gamma delta T-ce...

                            Brand Name : OmnImmune

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 22, 2023

                            Lead Product(s) : Allogeneic Gamma Delta T-cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $3.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth